STAT3 and cancer: Due to the role of STAT-3 in cancer initiation and development, multiple treatments aim to inhibit the IL-6/IL-6R/STAT-3 signaling pathway, one of these treatments is tocilizumab (Tcz), a humanized monoclonal antibody that binds to membrane-bound and soluble IL-6R to inhibit IL-6 signaling (15).